Werewolf Therapeutics, Inc.

NasdaqGS HOWL

Werewolf Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -62.12 M

Werewolf Therapeutics, Inc. Net Income is USD -62.12 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -75.57% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Werewolf Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -35.38 M, a 39.78% change year over year.
Werewolf Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -58.75 M, a -48.68% change year over year.
Werewolf Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -39.52 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGS: HOWL

Werewolf Therapeutics, Inc.

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years